Cargando…

SUN-350 Sterol-O-Acyl Transferase 1 Protein Expression Alone Is Not Sufficient to Predict Response to Mitotane Treatment in Adrenocortical Carcinoma

Background: Objective response rate to mitotane in advanced ACC is only ~20% and adverse drug effects are frequent and potentially serious. Markers of treatment response are not established. We have previously discovered that mitotane is an inhibitor of sterol-O-Acyl transferase 1 (SOAT1) which lead...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weigand, Isabel, Altieri, Barbara, Ferreira, Amanda, Basile, Vittoria, Landwehr, Laura-Sophie, Ronchi, Cristina, Schreiner, Jochen, Megerle, Felix, Berruti, Alfredo, Canu, Letizia, Volante, Marco, Paiva, Isabel, Della Casa, Silvia, Sbiera, Silviu, Fassnacht, Martin, Fragoso, Maria, Terzolo, Massimo, Kroiss, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Adrenal
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553006/ http://dx.doi.org/10.1210/js.2019-SUN-350

Ejemplares similares

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021)

SAT-354 Characterization of Cell Death Induced by SOAT1 Inhibition in Adrenocortical Carcinoma Cells
por: Weigand, Isabel, et al.
Publicado: (2019)

SUN-211 Active Steroid Hormone Synthesis Renders Adrenocortical Cells Highly Susceptible to Type II Ferroptosis Induction
por: Weigand, Isabel, et al.
Publicado: (2020)

CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma
por: Ronchi, Cristina L., et al.
Publicado: (2014)

Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma
por: Landwehr, Laura-Sophie, et al.
Publicado: (2020)

Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study
por: Elhassan, Yasir, et al.
Publicado: (2021)

Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study
por: Altieri, Barbara, et al.
Publicado: (2020)

THU617 Prolonged Exposure To Target Mitotane Concentrations Is Associated With Better Recurrence-free Survival In Patients With Adrenocortical Carcinoma On Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2023)

Investigating the Role of Cholesterol and Lipid Trafficking in Mitotane Resistance in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2021)

SAT-165 Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma
por: Lacombe, Amanda Meneses Ferreira, et al.
Publicado: (2020)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

SAT-LB064 Mitotane Induces Autophagy: A Mechanism to Promote Chemoresistance in Adrenocortical Carcinoma
por: Tompkins, Kenneth, et al.
Publicado: (2019)

SUN-216 Investigating the Role of the Liver X Receptor in Potentiating Mitotane Therapy in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2020)

ODP597 Clinical case of uncomplicated pregnancy in a patient with adrenocortical carcinoma during treatment with mitotane
por: Beltsevich, Dmitry, et al.
Publicado: (2022)

Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues?
por: Sbiera, Iuliu, et al.
Publicado: (2021)

SAT-350 Comparative Proteomic Analysis of Various Forms of Bilateral Adrenocortical Hyperplasia
por: Berthon, Annabel, et al.
Publicado: (2019)

CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells
por: Germano, Antonina, et al.
Publicado: (2018)

Evaluation of the Molecular Pathogenesis of Adrenocortical Tumors by Whole-Genome Sequencing
por: Neininger, Kerstin, et al.
Publicado: (2021)

Efficacy of Treatment With PARP Inhibitor and Immunotherapy for Aggressive Adrenocortical Carcinomawith Cushing’s Syndrome Refractory to Treatment With EDP Chemotherapy and Mitotane
por: Greb, Alexandra C, et al.
Publicado: (2021)

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
por: Puglisi, Soraya, et al.
Publicado: (2020)

OR04-5 Circulating Cell-Free DNA-Based Biomarkers For Prognostication and Disease Surveillance in Adrenocortical Carcinoma
por: Altieri, Barbara, et al.
Publicado: (2022)

ODP049 Oncocytic adrenocortical carcinoma misdiagnosed as renal oncocytoma and use of urinary steroid profiling in disease monitoring after mitotane therapy
por: Wong, Cheuk Lik, et al.
Publicado: (2022)

SAT-158 New Data on High Prevalence and Time of Occurrence of New Onset Hypothyroidism Associated with Mitotane Therapy in a Cohort of Adrenocortical Cancer
por: Poirier, Jonathan, et al.
Publicado: (2020)

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2019)

FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma
por: Tamburello, Mariangela, et al.
Publicado: (2022)

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
por: Basile, Vittoria, et al.
Publicado: (2020)

Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma
por: Liang, Raimunde, et al.
Publicado: (2020)

THU616 Analysis Of Germline Mutations In Patients With Sporadic Adrenocortical Carcinoma
por: Terzolo, Massimo, et al.
Publicado: (2023)

OR12-1 Activity of Abiraterone Acetate in the management of Cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial.
por: Abate, Andrea, et al.
Publicado: (2022)

Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications
por: Sbiera, Iuliu, et al.
Publicado: (2021)

Livin/BIRC7 expression as malignancy marker in adrenocortical tumors
por: Altieri, Barbara, et al.
Publicado: (2016)

THU609 Timeline For Undetectable Mitotane Plasma Levels In Adrenocortical Carcinoma Patients After Stopping Treatment
por: Younes, Nada, et al.
Publicado: (2023)

FRI199 Severe Hypertriglyceridemia And Acute Pancreatitis In A Patient With Adrenocortical Carcinoma (ACC) Taking Mitotane
por: Cortez, Briana Noel, et al.
Publicado: (2023)

PSAT096 Development and Validation of Mitotane Determination in Plasma Samples by LC-DAD
por: Lima-Valassi, Helena P, et al.
Publicado: (2022)

SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials
por: Kroiss, Matthias, et al.
Publicado: (2019)

Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction
por: Weigand, Isabel, et al.
Publicado: (2020)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
por: Germano, Antonina, et al.
Publicado: (2020)

Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994)

MicroRNAs and Long Non-Coding RNAs in Adrenocortical Carcinoma
por: Detomas, Mario, et al.
Publicado: (2022)

Clinical and Pathological Features of Metastatic Adrenocortical Carcinoma
por: Guiomar, Joana Reis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0gb4i29ijsd1nu87s9cf383mnh